A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
CompletedOBSERVATIONAL
Enrollment
1,088
Participants
Timeline
Start Date
October 14, 2020
Primary Completion Date
October 13, 2022
Study Completion Date
October 13, 2022
Conditions
Parkinson Disease
Interventions
DRUG
Equfina
Equfina oral tablets.
Trial Locations (2)
Unknown
Eisai Trial Site 2, Osaka
Eisai Trial Site 1, Tokyo
All Listed Sponsors
lead
Eisai Co., Ltd.
INDUSTRY
NCT04724109 - A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment) | Biotech Hunter | Biotech Hunter